No Data
No Data
Hengrui Medicine Gets Inspection Clearance From Jiangsu Province's Drug Regulator
Jiangsu Hengrui Medicine (SHA:600276) received a good manufacturing practice or GMP certificate from the drug regulator of China's Jiangsu Province after it passed regulatory inspection, according to
Jiangsu Hengrui Pharmaceuticals' (600276.SH) subsidiary passed the pharmaceutical GMP compliance inspection.
On July 7th, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Pharmacy Co., Ltd., recently received a "Drug GMP Compliance Inspection Results Notice" issued by the Jiangsu Provincial Drug Administration. Inspection conclusion: Based on the results of this inspection and the review of the Jiangsu Provincial Drug Administration, Suzhou Shengdiya Biomedical Pharmacy Co., Ltd. complies with the "Drug Production Quality Management Standard (2010 Revision)" and its appendix. This GMP compliance inspection indicates that the production of related pharmaceuticals of the company meets GMP requirements, and will help the company maintain stable production.
Jiangsu Hengrui Pharmaceuticals (600276.SH) will distribute a cash dividend of 0.2 yuan per share for the year 2023 on July 12.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the profit distribution plan for this time has been approved on May 15, 2024...
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Pulmonary Fibrosis Drug
Jiangsu Hengrui Medicine's (SHA:600276) subsidiary, Guangdong Hengrui Medicine, secured approval for clinical trial for its HRS-9813 tablets. HRS-9813 tablets are shown to improve lung function and pu
Jiangsu Hengrui Pharmaceuticals (600276.SH): Clinical trial application for HRS-9813 tablets approved.
Jiangsu Hengrui Pharmaceuticals (600276.SH) issued an announcement that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the approval notice of drug clinical trial for HRS-9813 from the National Medical Products Administration and will conduct clinical trials in the near future. HRS-9813 is a Category 1 innovative drug independently developed by the company. Preclinical mouse IPF efficacy data showed that HRS-9813 can significantly improve lung function and pulmonary fibrosis with good safety.
The Price Is Right For Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
With a price-to-earnings (or "P/E") ratio of 55.5x Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) may be sending very bearish signals at the moment, given that almost half of all companies in China
No Data